Want to see GALT full AI Analyst Report?
Galectin Therapeutics (GALT) Income Statement
Galectin Therapeutics Income Statement
Last quarter (Q2 2026), Galectin Therapeutics's total revenue was $0.00. In Q2, Galectin Therapeutics's net income was $-9.11M. See Galectin Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 20.09M | $ 42.43M | $ 38.07M | $ 38.35M | $ 30.18M | |
| Depreciation and Amortization | $ 53.00K | $ 37.00K | $ 33.00K | $ 32.00K | $ 41.00K |
| $ -23.45M | $ -41.47M | $ -38.24M | $ -37.71M | $ -30.00M | |
| $ -20.09M | $ -42.43M | $ -38.07M | $ -38.35M | $ -30.18M | |
| $ -10.75M | $ -4.61M | $ -2.99M | $ -424.00K | $ -348.00K | |
| $ -30.84M | $ -47.05M | $ -41.07M | $ -38.78M | $ -30.53M | |
| $ -30.84M | $ -47.05M | $ -41.07M | $ -38.78M | $ -30.53M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.48 | $ -0.76 | $ -0.74 | $ -0.65 | $ -0.52 |
| Diluted EPS | $ -0.48 | $ -0.76 | $ -0.74 | $ -0.65 | $ -0.52 |
| Weighted Average Shares Outstanding | 63.90M | 62.31M | 60.16M | 59.39M | 58.53M |
| Weighted Average Shares Outstanding (Diluted) | 63.90M | 62.31M | 60.16M | 59.39M | 58.53M |
Currency in USD